Select Page ::

Is SAGE Therapeutics Inc (SAGE) Stock Near the Top of the Biotechnology Industry? – InvestorsObserver

Posted on April 25, 2020 by Danzig

A rating of 18 puts SAGE Therapeutics Inc (SAGE) near the bottom of the Biotechnology industry according to InvestorsObserver. SAGE Therapeutics Inc's score of 18 means it scores higher than 18% of stocks in the industry. SAGE Therapeutics Inc also received an overall rating of 35, putting it above 35% of all stocks. Biotechnology is ranked 10 out of the 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

SAGE Therapeutics Inc (SAGE) stock is trading at $38.00 as of 1:22 PM on Friday, Apr 24, a rise of $1.76, or 4.86% from the previous closing price of $36.24. The stock has traded between $35.62 and $38.03 so far today. Volume today is light. So far 545,172 shares have traded compared to average volume of 1,562,765 shares.

To see InvestorsObserver's Sentiment Score for SAGE Therapeutics Inc click here.

Go here to see the original:
Is SAGE Therapeutics Inc (SAGE) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

FDA Clears the Way for Ridgeback Biotherapeutics to begin Human Testing of a Promising Potential Treatment for COVID-19 – BioSpace

Posted on April 12, 2020 by Danzig

EIDD-2801, an oral broad-spectrum antiviral proceeding into Clinical Trials

ATLANTA and MIAMI, April 6, 2020 /PRNewswire/ -- Ridgeback Biotherapeutics LP, a closely held biotechnology company, and Drug Innovations at Emory (DRIVE), LLC, a not-for-profit biotechnology company wholly owned by Emory University, today announced that the U.S. Food and Drug Administration (FDA) has approved an Investigational New Drug application by Drug Innovation Ventures at Emory (DRIVE), LLC, wholly owned by Emory University, for an orally available antiviral compound, EIDD-2801, exclusively licensed to Ridgeback Biotherapeutics, LP (Ridgeback), a closely held biotechnology company. This action by the FDA allows Ridgeback to initiate human clinical testing of EIDD-2801 in the United States.

"We are thankful to FDA Commissioner Dr. Steven Hahn and his team at the Anti-Viral Division for the unprecedented speed in reviewing our submission, the guidance and the highly collaborative process that ensures this promising drug can advance into the clinical development as fast as possible," said Wendy Holman, Chief Executive Officer of Ridgeback. "We also appreciate the guidance we have received from the Assistant Secretary of Preparedness and Response (ASPR), including discussions that occurred months before COVID-19 first emerged, to help Emory/DRIVE advance the development of EIDD-2801 as quickly as possible to address this global pandemic."

EIDD-2801 prevents the replication of SARS-CoV-2, the virus that causes COVID-19, and has shown potent activity against SARS-CoV and MERS-CoV in animal models of infection. In addition to coronaviruses, EIDD-2801 has broad spectrum activity against a number of diseases of public health concern, including influenza, chikungunya, Ebola, and equine encephalitis (VEE and EEE). The antiviral is orally available and, in addition to COVID-19, is being developed for the treatment of seasonal and pandemic influenza under a contract awarded to Emory Institute for Drug Development by the National Institute of Allergy and Infectious Diseases (NIAID) and for Venezuelan and Eastern equine encephalitis virus (VEEV and EEEV) by the Defense Threat Reduction Agency (DTRA).

"FDA's prompt approval of our IND allows us to initiate human testing for EIDD-2801 as quickly as possible," says George Painter, Ph.D., director of the Emory Institute for Drug Development (EIDD) and CEO of DRIVE. "We are grateful to our collaborators for helping us to assemble this application quickly, and to the FDA for expediting the process. An orally available antiviral medication would be a critical weapon for fighting COVID-19."

Ridgeback and DRIVE have established a partnership to advance EIDD-2801 through clinical development and to optimize availability during the current COVID-19 pandemic. EIDD-2801 was exclusively licensed to Ridgeback in March 2020.

"We look forward to our continued work with the highly experienced drug development team at DRIVE and the dedicated medical, public health and governmental personnel who are on the frontlines of this pandemic in the United States and abroad," says Wendy Holman, CEO of Ridgeback Biotherapeutics. "The ability to deliver promising treatments to patients in need is what makes us excited to come to work every day. Ridgeback brings its unique perspective, honed by our success developing an Ebola therapeutic during the 2018-2020 outbreak in the DR Congo, to help advance EIDD-2801 for the treatment of diseases that are critical to pandemics and global health."

About EIDD-2801:

EIDD-2801 is an orally bioavailable form of a highly potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV-2, the causative agent of COVID-19. In animal studies of two distinct coronaviruses (SARS-CoV1 and MERS), EIDD-2801 has been shown to improve pulmonary function, decrease body weight loss and reduce the amount of virus in the lung. In addition to activity against coronaviruses, EIDD-2801, in laboratory studies, has demonstrated activity against seasonal and bird influenza, respiratory syncytial virus, chikungunya virus, Ebola virus, Venezuelan equine encephalitis virus, and Eastern equine encephalitis virus. The development of EIDD-2801 has been funded in part with Federal funds from the National Institute of Allergy and Infectious Diseases (NIAID), under contract numbers HHSN272201500008C and 75N93019C00058, and from the Defense Threat Reduction Agency (DTRA), under contract numbers HDTRA1-13-C-0072 and HDTRA1-15-C-0075.

About Ridgeback Biotherapeutics LP:

Headquartered in Miami, Florida, Ridgeback Biotherapeutics is a privately held, majority woman-owned biotechnology company focused on orphan and infectious diseases. Initial funding for Ridgeback Biotherapeutics originated from Wayne and Wendy Holman; two individuals committed to investing in and supporting technologies that will make the world a better place. The team at Ridgeback is dedicated to working toward finding life-saving and life-changing solutions for patients and diseases that need champions. Ridgeback is in the process of completing a Biologics Licensing Application with the Food & Drug Administration for mAb114 (ansuvimab) for the treatment of Ebola. Ansuvimab development has been funded in whole or in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. 75A50119C00059 and 75A50120C0009.

About DRIVE:

DRIVE is a non-profit LLC wholly owned by Emory University and started as an innovative approach to drug development. Operating like an early stage biotechnology company, DRIVE applies focus and industry development expertise to efficiently translate discoveries to address viruses of global concern. DRIVE's mission is to discover and develop antiviral drugs for emerging infections, pandemic threats, and biodefense (e.g. COVID-19, swine flu, bird flu, dengue, chikungunya, Ebola, Zika, and viral encephalitis). Because these diseases are major threats, antiviral drugs are critically needed to treat them; however, they are generally not profitable enough for industry to pursue, and thus are considered neglected diseases. DRIVE is unique in that it brings industry expertise to the assets of a leading research University to develop potential antiviral drugs to a de-risked value inflection point that substantially increases the probability of the potential drug being licensed by industry and developed for the ultimate benefit of the public. DRIVE's executive team, led by George Painter, has over three decades of drug development experience within both large pharmaceutical and biotechnology companies, including leading the development of multiple FDA approved antivirals to treat HIV and Influenza, among other viral diseases, including AZT and Relenza.

About Defense Threat Reduction Agency:

The Defense Threat Reduction Agency (DTRA) was formally established on October 1, 1998. DTRA enables the Department of Defense, the United States Government and International partners to counter and deter weapons of mass destruction and improvised threat networks. As a Combat Support Agency and a Defense Agency, DTRA's mission is to counter the threats posed by the full spectrum of weapons of mass destruction (WMD), including chemical, biological, radiological, nuclear, and high-yield explosives; counter the threats posed by the growing, evolving categories of improvised threats, including improvised explosive devices, car bombs and weaponized consumer drones, as well as the tactics, technologies and networks that put them on the battlefield; and ensure the U.S. military maintains a safe, secure, effective and credible nuclear weapons deterrent.

View original content to download multimedia:http://www.prnewswire.com/news-releases/fda-clears-the-way-for-ridgeback-biotherapeutics-to-begin-human-testing-of-a-promising-potential-treatment-for-covid-19-301036307.html

SOURCE Ridgeback Biotherapeutics LP

View post:
FDA Clears the Way for Ridgeback Biotherapeutics to begin Human Testing of a Promising Potential Treatment for COVID-19 - BioSpace

Industry Breakdown: Where Does Trillium Therapeutics Inc (TRIL) Stock Fall in the Biotechnology Field? – InvestorsObserver

Posted on April 8, 2020 by Danzig

The 88 rating InvestorsObserver gives to Trillium Therapeutics Inc (TRIL) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 100 percent of stocks in the Biotechnology industry, TRILs 88 overall rating means the stock scores better than 88 percent of all stocks.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 88 would rank higher than 88 percent of all stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Trillium Therapeutics Inc (TRIL) stock is trading at $4.23 as of 1:51 PM on Monday, Apr 6, an increase of $0.57, or 15.57% from the previous closing price of $3.66. The stock has traded between $3.76 and $4.31 so far today. Volume today is less active than usual. So far 1,151,186 shares have traded compared to average volume of 3,800,958 shares.

To see InvestorsObserver's Sentiment Score for Trillium Therapeutics Inc click here.

See the rest here:
Industry Breakdown: Where Does Trillium Therapeutics Inc (TRIL) Stock Fall in the Biotechnology Field? - InvestorsObserver

Biotechnology Industry: Does Theravance Biopharma Inc (TBPH) Stock Beat its Rivals? – InvestorsObserver

Posted on April 8, 2020 by Danzig

Theravance Biopharma Inc (TBPH) is around the middle of the Biotechnology industry according to InvestorsObserver. TBPH received an overall rating of 62, which means that it scores higher than 62 percent of all stocks. Theravance Biopharma Inc also achieved a score of 64 in the Biotechnology industry, putting it above 64 percent of Biotechnology stocks. Biotechnology is ranked 12 out of the 148 industries.

Theravance Biopharma Inc (TBPH) stock is trading at $21.24 as of 1:16 PM on Wednesday, Apr 1, a loss of -$1.87, or -8.09% from the previous closing price of $23.11. The stock has traded between $20.97 and $22.85 so far today. Volume today is low. So far 90,893 shares have traded compared to average volume of 463,876 shares.

To see InvestorsObserver's Sentiment Score for Theravance Biopharma Inc click here.

Read the original here:
Biotechnology Industry: Does Theravance Biopharma Inc (TBPH) Stock Beat its Rivals? - InvestorsObserver

Biotech Firms May Be Key To Beating The Coronavirus, But They’re Not Immune To Financial Worry – WBUR

Posted on April 11, 2020 by Danzig

Scott Robinson used to be an investment banker, so he has a pretty good idea why it's tough these days to raise money for his Cambridge biotechnology startup, MicroQuin even though the company believes its approach to fighting cancer could show promise against the coronavirus.

"At the moment, a lot of the funding has really been allocated to things that people are thinking are quick wins stuff like drug repurposing or vaccinations," he said.

For a handful of drugmakers taking on the coronavirus, fundraising is no problem right now. But for many other Massachusetts biotechs, the pandemic threatens to stop the flow of money.

If you're a company like MicroQuin, and you don't have a coronavirus vaccine candidate or a drug ready to test against COVID-19 good luck getting new financing.

And there's no telling when investors will feel comfortable spending again.

"We've seen many investors sort of push the pause button for the next quarter, as they assess the market," saidJonathan Norris, a managing director at Silicon Valley Bank. He spoke this week on a virtual panel organized by LabCentral, the Kendall Square workspace where Robinson's company and about 70 others are based.

"We just don't know how long this pandemic is going to last," Norris said. "The big financial questions that investors are talking about are, 'What's going to happen in the public markets? Will IPOs happen?'"

Initial public offerings of stock can be critical to biotechs. They often infuse cash into young firms that have raised venture capital but don't yet have any FDA-approved drugs to produce revenue.

The Nasdaq Biotechnology Index has recovered some losses, after falling more than 20% last month. But it's still a scary time, said Robert Urban, the former head of Johnson & Johnson's innovation division. J&J has secured a $1 billiondeal including federal grants to try to develop a vaccine, but most companies aren't in that position.

"We have some tough days ahead and maybe tough months ahead," Urban said of the biotech industry. "So, anyone who's running a business a life science business, in some ways, may be even more difficult because they require so much money needs to be taking some very careful care of the decisions that they make."

Urban and Norris were joined on the LabCentral panel by Matt McTygue, an attorney who represents venture capitalists. It's not that investors aren't doing any deals, McTygue said, but he offered a warning: "Financings that do happen during this time are going to be on more investor-favorable terms, more dilutive terms."

In other words, entrepreneurs who are desperate for funding may have to give up bigger-than-usual ownership stakes in their companies.

Why Lakeland Industries, Alpha Pro Tech, and Vir Biotechnology Briefly Skyrocketed and Crashed Today – Motley Fool

Posted on February 29, 2020 by Danzig

What happened

Investors in Lakeland Industries (NASDAQ:LAKE), Alpha Pro Tech (NYSEMKT:APT), and Vir Biotechnology(NASDAQ:VIR) are experiencing a wild end to the trading week. Shares of these companies rose as much as 40%, 65%, and 20%, respectively, in early-morning trading on Friday. However, all three of them have since reversed course and have come crashing back down to earth. At their lowest points, they were down 13%, 34%, and 36%, respectively.

As of 2:57 p.m. EST, shares of Lakeland Industries up about 1% while shares of Alpha Pro Tech and Vir Biotechnology were down 9% and 30%, respectively.

You're probably aware that fears of the spread of the COVID-19 (the illness caused by a novel coronavirus) are wreaking havoc on the public market this week. TheDow Jones Industrial Average(DJINDICES: ^DJI),S&P 500(SNPINDEX: ^GSPC), andNasdaq Compositehave all dropped more than 10% from their recent highs in the last five days. That's a remarkably big move in such a short period of time.

At the same time, traders have been going crazy for any stock that is poised to benefit from the coronavirus. Lakeland Industries,Vir Biotechnology, andAlpha Pro Tech have all been identified as "Coronavirus stocks" this week and have gone parabolic in response.

Image source: Getty Images.

Lakeland Industries, which sells industrial protective clothing such ascoveralls and laboratory coats, has surged 47% in the last five days. The only news out of the company during that time is that is participating in an upcoming investor conference. Traders are probably bidding up shares on the hope that demand for its products has surged in the last few weeks.

Vir Biotechnology, which is aclinical-stage immunology company, isup 158% in the last week. A lot of the sudden bullishness is traceable to the announcement that it has partnered with a Chinese drug maker to develop a potentialtreatment for Coronavirus.

Alpha Pro Tech's returns top them all. Like Lakeland Industries, Alpha Pro Tech sells protective apparel such as gowns, coveralls, face masks, and more. Shares of this normally sleepy stock are up an incredible 317% in the last five trading days, which is a remarkable move. Management announced yesterday that has booked $14 million in orders for its N-95 Face mask, which is a sizable order for the small-cap.

It's impossible for investors to know what the fallout from the coronavirus will be and how that will impact the markets. However, it's likely that stock prices are going to remain extremely volatile as long as thecoronavirus continues to dominate the headlines.

It might seem tempting to buy into stocks that could see a short-term benefit from the continued spread of the coronavirus disease, but that is probably unwise in the long term given that the virus will eventually be contained.

Personally, I had no interest in any of these companies prior to their recent jump, and I see no reason to be bullish on them today. That's why my plan remains to focus my time and capital on companies that are poised to grow rapidly even if it takes a long time for governments to get thecoronavirus under control.

Link:
Why Lakeland Industries, Alpha Pro Tech, and Vir Biotechnology Briefly Skyrocketed and Crashed Today - Motley Fool

Industry Analysis: Should You Buy Provention Bio Inc (PRVB) in Biotechnology? – InvestorsObserver

Posted on March 5, 2020 by Danzig

Provention Bio Inc (PRVB) is near the top in its industry group according to InvestorsObserver. PRVB gets an overall rating of 82. That means it scores higher than 82 percent of stocks. Provention Bio Inc gets a 96 rank in the Biotechnology industry. Biotechnology is number 21 out of 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Provention Bio Inc (PRVB) stock is trading at $11.46 as of 2:34 PM on Tuesday, Mar 3, a drop of -$0.78, or -6.37% from the previous closing price of $12.24. The stock has traded between $11.31 and $12.71 so far today. Volume today is less active than usual. So far 305,664 shares have traded compared to average volume of 536,536 shares.

To see InvestorsObserver's Sentiment Score for Provention Bio Inc click here.

Pharmaceutical and Biotechnology Market 2030 Is Booming Across the Globe Explored in Latest Research with Top Key Players. – Melanian News

Posted on January 24, 2020 by Danzig

The Germany Geotechnical Engineering & Instrumentation market represents the significant growth prospects during the forecast period 2019-2025. The detailed report provides in-depth analysis and identifies the market dynamics in the Germany Geotechnical Engineering & Instrumentation market.

The market growth is estimated by various determinants including:

The study of the above-mentioned market determinants provides overall market insights. The research report titled Germany Geotechnical Engineering & InstrumentationMarket is compiled by Report Ocean, the report detailed about various market segments, profiling market players and many more.

Click Here For Our Free Complimentary Sample Report: A Brief Introduction of the research report, TOC, List of Tables and Figures, Competitive Landscape and Geographic Segmentation, Innovation and Future Developments

https://www.reportocean.com/industry-verticals/sample-request?report_id=BIZ301

Market players adopt various market-related strategies to withstand market competition in the long-term. Some of the market strategies adopted new product launches, mergers & acquisitions, partnerships, business expansions, collaborations, partnerships, and agreements.

Key players present in the market are listed in the company profile chapter of the research report, some of the companies are enlisted below

Mannvit hf, SGS SA, Intertek Group plc, SSF Ingenieure, Cowi A/S, PZP engineers AG, EDR GmbH, Keller Group PLC, Fugro N.V., BW engineers GmbH, and AECOM Ltd.

Market forecast was calculated by analyzing market spending patterns in-depth, it is also based upon a market model that is derived from market connectivity, various dynamics, and market-related other growth factors. These calculations are based upon analytical results derived from various authentic web sources such as journals, research papers, company websites, annual reports published by companies, government websites and other reliable sources of information.

Request a Sample of the Germany Geotechnical Engineering & Instrumentation market report @ https://www.reportocean.com/industry-verticals/sample-request?report_id=BIZ301

The Germany Geotechnical Engineering & InstrumentationMarket Research report analyzes various topics such as-

The Germany Geotechnical Engineering & InstrumentationMarket Research report provides insights on-

In the Germany Geotechnical Engineering & InstrumentationMarket research report, the industry was analyzed by fragmenting the market into various segmentations,that were studied in detail to analyze the market, market segmentations are on the basis of

On the basis of Service, the Germany Geotechnical Engineering & Instrumentation Market is studied across Geotechnical Field Investigation and Geotechnical Laboratory Testing.

On the basis of End User, the Germany Geotechnical Engineering & Instrumentation Market is studied across Commercial, Industrial, Infrastructure, and Residential.

Research Methodology

Report Ocean adopts various research methodologies to collect the data required to compile an extensively researched market study. The company conducts primary research among market players, market leaders, stakeholders, and others to collect the data. Also, secondary research is used to collect the data and filter it according to the requirement of analyses. Research analysts with domain expertise play a very crucial role to choose a type of research methodology and methods to implement the plan for effective market study.

Various sources of information are:

Following the process of data collection, various economic parameters adopted and numerous statistical software were used to estimate the market size and calculate the market share considering several factual databases and data pointers. The detailed research process involves data mining as a crucial process of research methodology. The client-specific research study focused majorly on customer-focused research by the 360-degree market study.

Key Questions Answered:

The report covers the following chapters

There are 13 Chapters to thoroughly display the Germany Geotechnical Engineering & Instrumentation market. This report included the analysis of market overview, market characteristics, industry chain, competition landscape, historical and future data by types, applications, and regions.

Chapter 1: Germany Geotechnical Engineering & Instrumentation Market Overview, Product Overview, Market Segmentation, Market Overview of Regions, Market Dynamics, Limitations, Opportunities and Industry News and Policies.

Chapter 2: Germany Geotechnical Engineering & Instrumentation Industry Chain Analysis, Upstream Raw Material Suppliers, Major Players, Production Process Analysis, Cost Analysis, Market Channels, and Major Downstream Buyers.

Chapter 3: Value Analysis, Production, Growth Rate and Price Analysis by Type of Germany Geotechnical Engineering & Instrumentation.

Chapter 4: Downstream Characteristics, Consumption and Market Share by Application of Germany Geotechnical Engineering & Instrumentation.

Chapter 5: Production Volume, Price, Gross Margin, and Revenue ($) of Germany Geotechnical Engineering & Instrumentation by Regions.

Chapter 6: Germany Geotechnical Engineering & Instrumentation Production, Consumption, Export, and Import by Regions (2014-2019).

Chapter 7: Germany Geotechnical Engineering & Instrumentation Market Status and SWOT Analysis by Regions.

Chapter 8: Competitive Landscape, Product Introduction, Company Profiles, Market Distribution Status by Players of Germany Geotechnical Engineering & Instrumentation.

Chapter 9: Germany Geotechnical Engineering & Instrumentation Market Analysis and Forecast by Type and Application.

Chapter 10: Market Analysis and Forecast by Regions.

Chapter 11: Industry Characteristics, Key Factors, New Entrants SWOT Analysis, Investment Feasibility Analysis.

Chapter 12: Market Conclusion of the Whole Report.

Chapter 13: Appendix Such as Methodology and Data Resources of This Research.

..and view more in complete table of Contents

Check Complete Report Details @ https://www.reportocean.com/industry-verticals/details?report_id=BIZ301

Get in Touch with Us:

Jyoti

Email: [emailprotected]

Tel:+1 888 212 3539 (US TOLL FREE); +91-9997112116

Website:https://www.reportocean.com/

View original post here:
Pharmaceutical and Biotechnology Market 2030 Is Booming Across the Globe Explored in Latest Research with Top Key Players. - Melanian News

Is Oncolytics Biotech, Inc. (ONCY) a Winner or a Loser in the Biotechnology Industry – InvestorsObserver

Posted on January 29, 2020 by Danzig

Oncolytics Biotech, Inc. (ONCY) is near the top in its industry group according to InvestorsObserver. ONCY gets an overall rating of 78. That means it scores higher than 78 percent of stocks. Oncolytics Biotech, Inc. gets a 94 rank in the Biotechnology industry. Biotechnology is number 55 out of 148 industries.

Click Here to get the full Stock Score Report on Oncolytics Biotech, Inc. (ONCY) Stock.

Oncolytics Biotech, Inc. (ONCY) stock is trading at $3.11 as of 9:57 AM on Monday, Jan 27, a loss of -$0.16, or -5.05% from the previous closing price of $3.27. The stock has traded between $3.00 and $3.35 so far today. Volume today is below average. So far 349,770 shares have traded compared to average volume of 2,557,054 shares.

To see InvestorsObserver's Sentiment Score for Oncolytics Biotech, Inc. click here.

Link:
Is Oncolytics Biotech, Inc. (ONCY) a Winner or a Loser in the Biotechnology Industry - InvestorsObserver

The Benchmark Company Expands Its Biotechnology Focus With The Addition Of Dr. Aydin Huseynov And Dr. Okechukwu Linton – GlobeNewswire

Posted on February 26, 2020 by Danzig

NEW YORK, Feb. 26, 2020 (GLOBE NEWSWIRE) -- The Benchmark Company, LLC, an institutionally focused research, sales & trading, and investment banking firm covering multiple sectors, including biotechnology and healthcare, technology, media and telecom (TMT), business services, and industrials, is pleased to announce that Aydin Huseynov, M.D., CFA has joined the Firm as Managing Director, Senior Biotechnology Analyst and Okechukwu Linton, M.D. has joined the Firm as Vice President, Investment Banking.

Dr. Huseynov joins Benchmark from Oppenheimer & Co. Inc. where he was on the Biotechnology Equity Research team. Prior to Oppenheimer, Dr. Huseynov worked as a strategy consultant at Syneos Health Consulting where he advised biopharma companies in R&D, clinical, commercial, valuation and market access projects, and as a corporate strategist at Teva Pharmaceuticals. Earlier in his career, he was a practicing physician and entrepreneur. Dr. Huseynov holds an MBA degree from The Fuqua School of Business, Duke University, an M.D. from Azerbaijan Medical University and an MS in International Economic Relations from Khazar University. He is also a CFA Charterholder.

Prior to joining Benchmark, Dr. Linton was the founder and manager of Skymedicine and was a lead author for Rosh Review, both medical education e-learning companies. Dr. Linton has trained in both radiation oncology and internal medicine. He has worked in the Indiana University Proton Therapy Center conducting retrospective studies on malignancies of the head and neck. He has also studied issues of healthcare quality, efficiency, and access. Dr. Linton earned an MBA from Harvard Business School, an M.D. from Harvard Medical School, and an AB from Harvard College.

We are excited to continue the expansion of Benchmarks healthcare franchise following the recent additions of Edward Rubin as Co-Head of Investment Banking who focuses primarily on the biotechnology and healthcare sectors, and Robert Wasserman as Senior Biotechnology Analyst. Our new hires, together with John Borer, Co-Head of Investment Banking, Bruce Jackson, the Firms Senior Healthcare Tech Analyst, and Bill Sutherland, the Firms Healthcare Services Analyst have created a meaningful platform from which to service both issuers and institutional investors in the healthcare arena said Richard Messina, Founder and President of The Benchmark Company.

Mr. Rubin added: Benchmark has had a strong start to its 2020 biotechnology investment banking activities having acted as sole book running manager for the follow-on offering of straight common stock for Seelos Therapeutics, Inc. and as joint book running manager for the Series A Preferred Stock offering of Fortress Biotech, Inc. I believe the addition of Aydin and Oke to Benchmarks existing personnel will further accelerate our activities in the space.

About The Benchmark Company, LLC

Founded in 1988 and based in New York City with offices in San Francisco, Boston and Milwaukee, The Benchmark Company covers institutional and corporate clients with its research, sales & trading, and investment banking capabilities. The firm has built a reputation for delivering superior client service, market access, and in-depth market and industry expertise. At Benchmark, we are committed to our clients success. Our team of experienced professionals works closely with our clients to understand their unique needs and goals to offer sound, unbiased guidance by drawing on the significant resources from across the firms services platform. This collaborative Benchmark Team approach is focused solely on partnering with our clients to provide significant value and build a long-term relationship. https://www.benchmarkcompany.com/

For further information please contact:

Elise Stern

Managing Director, Institutional Equities & Corporate Services

150 East 58th Street 17th Floor | New York, New York 10155D: 212-312-6747 | estern@benchmarkcompany.com

Member FINRA/SIPC

Excerpt from:
The Benchmark Company Expands Its Biotechnology Focus With The Addition Of Dr. Aydin Huseynov And Dr. Okechukwu Linton - GlobeNewswire

Best Informative Report on Biotechnology Market Insights 2019 to 2024 | key players F. Hoffmann-La Roche Ltd, Pfizer, Merck& Co., Sanofi,…

Posted on December 24, 2019 by Danzig

Research N Reports proclaims a new addition of informative data titled Biotechnology market to its extensive database. The main purpose of the report centers on providing an in-depth analysis, which clearly explains how recent advancements and new trends could potentially affect the future of Biotechnology market during the forecast period. The global Biotechnology report is thus a source of insightful data, which helps to make erudite business decisions.

Key Companies- F. Hoffmann-La Roche Ltd, Pfizer, Merck& Co., Sanofi, AstraZeneca, Gilead and more

Apply for Best sample @ https://healthcareintelligencemarkets.com/request_sample.php?id=128077

The information for each competitor includes:

With the help of an array of financial facts and figures, an effective graphical presentation is presented. Techniques such as, graphs, charts, diagrams and tables ensure a lucid understanding of few complexities to the readers. Additionally, the report draws attention to historical developments and futuristic innovations to gauge the difference between existing and upcoming Biotechnology strategies.

Get Attractive discount @ https://healthcareintelligencemarkets.com/ask_for_discount.php?id=128077

Table of Contents:

For information, please visit @ https://healthcareintelligencemarkets.com/enquiry_before_buying.php?id=128077

About Research N Report:

Research N Reports is a new age market research firm where we focus on providing information that can be effectively applied. Today being a consumer-driven market, companies require information to deal with the complex and dynamic world of choices. Where relying on a soundboard firm for your decisions becomes crucial. Research N Reports specializes in industry analysis, market forecasts and as a result getting quality reports covering all verticals, whether be it gaining perspective on current market conditions or being ahead in the cut-throat global competition. Since we excel at business research to help businesses grow, we also offer consulting as an extended arm to our services which only helps us gain more insight into current trends and problems. Consequently, we keep evolving as an all-rounder provider of viable information under one roof.

Sunny Denis

Sales Manager

Research N Reports

10916, Gold Point Dr, Houston, TX, Pin 77064.

+1-8886316977

Email: sales@researchnreports.com

Website: http://www.researchnreports.com

Biotechnology | Advanced Academic Programs | Johns Hopkins …

Posted on December 24, 2019 by Danzig

Johns Hopkins is a world leader in biological research and the global biotechnology industry. We challenge students with a rigorous, multi-disciplinary curriculum that fully prepares them to advance their careers and pursue their academic ambitions in the biotechnology field.MS in BiotechnologyFormatOnline and Onsite (Baltimore, MD)Entry TermsFall, Spring, and SummerDegree Requirements10 coursesLength of Program12 24 monthsTuition$4,495 per course

The Johns Hopkins MS in Biotechnology offers a comprehensive exploration of basic science, applied science, and lab science, with an industry focus. The program gives you a solid grounding in biochemistry, molecular biology, cell biology, genomics, and proteomics.

This 10-course degree program is thesis-optional and can be completed fully online. Students can enroll part-time or full-time. This Program offers a sufficient number of onsite courses to sustain students coming to the US on visas. Our curriculum will prepare you to engage in research, lead lab teams, make development and planning decisions, create and apply research modalities to large projects, and take the reins of management and marketing decisions.

Many students like the flexibility of the general degree; it allows them to tailor the coursework to meet their individual career goals. The program also offers six different concentrations: biodefense, bioinformatics, biotechnology enterprise, regenerative and stem cell technologies, regulatory affairs, or drug discovery.

Onsite courses are taught during evenings or weekends at either the universitys Homewood Campus in Baltimore, MD.

Note: Students should be aware of state-specific information for online programs. For more information, please contact an admissions representative.

Read the rest here:
Biotechnology | Advanced Academic Programs | Johns Hopkins ...

Solomon Page Healthcare & Life Sciences Division Expands its Global Footprint within the Pharmaceutical, Biotechnology, Medical Device and…

Posted on January 21, 2020 by Danzig

NEW YORK, Jan. 21, 2020 /PRNewswire/ -- Solomon Page, a leading global executive search firm servicing the Healthcare and Life Sciences industries, drives expansion through the hire of industry expert Luigi Frezza, who was named Managing Director, Life Sciences. Reporting into President & Global Practice Leader Marc Gouran, Frezza will be based in the London office and drive the growth of the Life Sciences team globally; partnering with companies in the Pharmaceutical, Biotech, Medical Devices and Diagnostics sectors.

Based in Manhattan, NY and with office locations throughout the U.S. and Europe, Solomon Page will continue to serve as a global partner in healthcare and life sciences executive search, while simultaneously expanding the company's footprint into new markets. "Our legacy of success spans across every branch of the Healthcare industry," Gouran said. "With Luigi now leading our Life Sciences practice based in London, we will continue to grow our global network by providing premiere consultative services and best-in-class solutions to both longstanding partners and new clients."

In support of this expansion, additional hires include Vice President Kristen Dorn and Consultant Shanon Yeow, who are both based in the recently opened Conshohocken, Pa. office.

Before joining Solomon Page, Frezza led the Pharmaceutical and Biotech practice of a medium-sized, boutique executive search firm across Europe and the U.S. With over 15 years of experience in the industry, including time spent at Korn Ferry, Frezza has an extensive background in working on search mandates across multiple functions, with a focus on senior roles in R&D, Technical and Commercial Operations, General Management as well as a broad range of corporate functional roles. "I am thrilled to be joining Marc and his team to support the growth of Solomon Page Healthcare & Life Sciences business on an international level," said Frezza. "In conjunction with Shanon and Kristen's efforts, the expansion of our Life Sciences division will round-out our full scope of services within the Healthcare sector. We look forward to making an impact on the industry by providing our clients, who trust us for our knowledge and experience, with valuable insight and unprecedented results."

About Solomon Page Founded in 1990, Solomon Page is a specialty niche provider of recruitment and executive search solutions across a wide array of functions and industries. The success of Solomon Page reflects an organic growth strategy supported by a highly entrepreneurial culture. Acting as a strategic partner to clients and candidates, Solomon Page focuses on providing customized solutions and building long-term relationships based on trust, respect, and the consistent delivery of excellent results. For additional information, visit solomonpage.com.

SOURCE Solomon Page

What Are Examples of Biotechnology? | Reference.com

Posted on January 8, 2019 by Danzig

Some examples of biotechnology include human gene therapy, genetically modifying plants and changing the genes of bacteria. Biotechnology helps improve crops so they produce more, healthier produce. It also helps fight human diseases.

Biotechnology is generally involved in changing the genes of a an organism to get the desired result. It affects the most people through genetically modified crops. Genetic modification of crops started thousands of years ago through selective breeding for preferred traits, but with the advances in technology in the modern day, scientists are able to directly manipulate genes. These plants produce higher quality food at a higher rate, and are often resistant to pests and diseases, which helps feed larger amounts of people for a lower price on less land.

Biotechnology more directly helps humans with gene therapy and the modification of bacteria to produce insulin for patients with diabetes. Gene therapy can help reduce or remove the effects of a disease, such as cancer or AIDS, but is still mostly in research and development. This type of therapy is still promising and has had good results in testing phases. Modified bacteria cells that produce insulin as they age helps treat and control the effects of diabetes in humans over time.

The rest is here:
What Are Examples of Biotechnology? | Reference.com

Does Apex Biotechnology (TPE:1733) Have A Healthy Balance Sheet? – Simply Wall St

Posted on December 19, 2019 by Danzig

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that Volatility is far from synonymous with risk. So it might be obvious that you need to consider debt, when you think about how risky any given stock is, because too much debt can sink a company. As with many other companies Apex Biotechnology Corp. (TPE:1733) makes use of debt. But should shareholders be worried about its use of debt?

Generally speaking, debt only becomes a real problem when a company cant easily pay it off, either by raising capital or with its own cash flow. In the worst case scenario, a company can go bankrupt if it cannot pay its creditors. However, a more usual (but still expensive) situation is where a company must dilute shareholders at a cheap share price simply to get debt under control. Having said that, the most common situation is where a company manages its debt reasonably well and to its own advantage. The first thing to do when considering how much debt a business uses is to look at its cash and debt together.

View our latest analysis for Apex Biotechnology

The chart below, which you can click on for greater detail, shows that Apex Biotechnology had NT$408.7m in debt in September 2019; about the same as the year before. But on the other hand it also has NT$482.4m in cash, leading to a NT$73.8m net cash position.

Zooming in on the latest balance sheet data, we can see that Apex Biotechnology had liabilities of NT$532.6m due within 12 months and liabilities of NT$515.4m due beyond that. Offsetting these obligations, it had cash of NT$482.4m as well as receivables valued at NT$430.3m due within 12 months. So it has liabilities totalling NT$135.2m more than its cash and near-term receivables, combined.

Given Apex Biotechnology has a market capitalization of NT$2.83b, its hard to believe these liabilities pose much threat. However, we do think it is worth keeping an eye on its balance sheet strength, as it may change over time. While it does have liabilities worth noting, Apex Biotechnology also has more cash than debt, so were pretty confident it can manage its debt safely.

It is just as well that Apex Biotechnologys load is not too heavy, because its EBIT was down 55% over the last year. Falling earnings (if the trend continues) could eventually make even modest debt quite risky. Theres no doubt that we learn most about debt from the balance sheet. However, not all investment risk resides within the balance sheet far from it. For example, weve discovered 2 warning signs for Apex Biotechnology which any shareholder or potential investor should be aware of.

Finally, a company can only pay off debt with cold hard cash, not accounting profits. While Apex Biotechnology has net cash on its balance sheet, its still worth taking a look at its ability to convert earnings before interest and tax (EBIT) to free cash flow, to help us understand how quickly it is building (or eroding) that cash balance. During the last three years, Apex Biotechnology produced sturdy free cash flow equating to 59% of its EBIT, about what wed expect. This cold hard cash means it can reduce its debt when it wants to.

While it is always sensible to look at a companys total liabilities, it is very reassuring that Apex Biotechnology has NT$73.8m in net cash. So we are not troubled with Apex Biotechnologys debt use. While Apex Biotechnology didnt make a statutory profit in the last year, its positive EBIT suggests that profitability might not be far away. Click here to see if its earnings are heading in the right direction, over the medium term.

Of course, if youre the type of investor who prefers buying stocks without the burden of debt, then dont hesitate to discover our exclusive list of net cash growth stocks, today.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

See the original post here:
Does Apex Biotechnology (TPE:1733) Have A Healthy Balance Sheet? - Simply Wall St

Agricultural Biotechnology Market Analysis With Top Companies, Applications, Trends And Forecasts to 2026 – amitnetserver

Posted on May 1, 2020 by Danzig

LGC Biosearch Technologies

The authors of the report shed light on lucrative business prospects, prominent trends, regulatory situations, and price scenarios of the global Agricultural Biotechnology market. Importantly, the report gives a detailed analysis of macroeconomic and microeconomic factors impacting the growth of the global Agricultural Biotechnology market. It is divided into various sections and chapters to help with easy understanding of each and every aspect of the global Agricultural Biotechnology market. Market players can use the report to peep into the future of the global Agricultural Biotechnology market and bring important changes to their operating style and marketing tactics to achieve sustained growth.

The research process begins with internal and external sources to obtain qualitative and quantitative information related to the Agricultural Biotechnology Market. It also provides an overview and forecast for the Agricultural Biotechnology Market based on all the segmentation provided for the global region. The predictions highlighted in the Agricultural Biotechnology Market share report have been derived using verified research procedures and assumptions. By doing so, the research report serves as a repository of analysis and information for every component of the Agricultural Biotechnology Market.

Ask For Discount (Exclusive Offer) @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=35624&utm_source=AMR&utm_medium=009

The Global Agricultural Biotechnology Market Report profoundly studies past and present phase provide valuable and reliable forecast estimation that drives Agricultural Biotechnology Market player to obtain comprehensive market scenario for near future. It facilitates Neobanking manufacturers and company officials with analysis based on upcoming investment opportunities, challenges, risks, and threats and prompts them to precisely plan their future activities.

The Global Agricultural Biotechnology Market is studied on the basis of key geographies North America, Europe, Asia Pacific, Central & South America and Middle East and Africa. North America dominated the Global Agricultural Biotechnology Market in 2019. U.S. market accounted for the majority of the market in this region in 2019, which is expected to continue over the forecast period.

Table of Content

1 Introduction of Agricultural Biotechnology Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Agricultural Biotechnology Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Agricultural Biotechnology Market, By Deployment Model

5.1 Overview

6 Agricultural Biotechnology Market, By Solution

6.1 Overview

7 Agricultural Biotechnology Market, By Vertical

7.1 Overview

8 Agricultural Biotechnology Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Agricultural Biotechnology Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Complete Report is Available @ https://www.verifiedmarketresearch.com/product/agricultural-biotechnology-market/?utm_source=AMR&utm_medium=009

About us:

Verified market research partners with the customer and offer an insight into strategic and growth analyzes, Data necessary to achieve corporate goals and objectives. Our core values are trust, integrity and authenticity for our customers.

Analysts with a high level of expertise in data collection and governance use industrial techniques to collect and analyze data in all phases. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research reports.

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: [emailprotected]

Tags: Agricultural Biotechnology Market Size, Agricultural Biotechnology Market Trends, Agricultural Biotechnology Market Growth, Agricultural Biotechnology Market Forecast, Agricultural Biotechnology Market Analysis

Online Biotechnology Bachelor’s Degree | UMUC

Posted on January 8, 2019 by Danzig

In addition to the general education requirements and the major, minor, and elective requirements, the overall requirements listed below apply to all bachelor's degrees.

Double majors: You can earn a dual major upon completion of all requirements for both majors, including the required minimum number of credits for each major and all related requirements for both majors. The same class cannot be used to fulfill requirements for more than one major. Certain restrictions (including use of credit and acceptable combinations of majors) apply for double majors. You cannot major in two programs with excessive overlap of required coursework. Contact an admissions advisor before selecting a double major.

Second bachelor's degree: To earn a second bachelor's degree, you must complete at least 30 credits through UMUC after completing the first degree. The combined credit in both degrees must add up to at least 150 credits. You must complete all requirements for the major. All prerequisites apply. If any of these requirements were satisfied in the previous degree, the remainder necessary to complete the minimum 30 credits of new classes should be satisfied with classes related to your major. You may not earn a second bachelor's degree in general studies and may not obtain a second associate's degree within the second bachelor's degree. Contact an admissions advisor before pursuing a second bachelor's degree.

Electives: Electives can be taken in any academic discipline. No more than 21 credits can consist of vocational or technical credit. Pass/fail credit, up to a maximum of 18 credits, can be applied toward electives only.

See the original post:
Online Biotechnology Bachelor's Degree | UMUC

Industry Analysis: Should You Buy Menlo Therapeutics Inc (MNLO) in Biotechnology? – InvestorsObserver

Posted on February 26, 2020 by Danzig

The 52 rating InvestorsObserver gives to Menlo Therapeutics Inc (MNLO) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 58 percent of stocks in the Biotechnology industry, MNLOs 52 overall rating means the stock scores better than 52 percent of all stocks.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 52 means the stock is more attractive than 52 percent of stocks.

Menlo Therapeutics Inc (MNLO) stock is down -25.04% while the S&P 500 is higher by 1.31% as of 11:27 AM on Wednesday, Feb 26. MNLO has fallen -$1.10 from the previous closing price of $4.40 on volume of 571,556 shares. Over the past year the S&P 500 has risen 13.43% while MNLO has fallen -61.04%. MNLO lost -$2.96 per share the over the last 12 months.

To screen for more stocks like MNLO click here.

Read the rest here:
Industry Analysis: Should You Buy Menlo Therapeutics Inc (MNLO) in Biotechnology? - InvestorsObserver

Compass Therapeutics to Present at the 40th Cowen Health Care Conference – Business Wire

Posted on February 29, 2020 by Danzig

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Compass Therapeutics, a clinical-stage biotechnology company targeting the human immune synapse with a new generation of monoclonal and multispecific antibody therapeutics, today announced that Thomas Schuetz, M.D., Ph.D., co-founder and chief executive officer, will present a company overview at the 40th Annual Cowen Health Care Conference in Boston on Tuesday, March 3, 2020.

Dr. Schuetzs presentation will feature an update on the ongoing Phase 1 trial of the companys lead candidate, CTX-471, a fully human agonistic antibody of CD137 being evaluated in patients with advanced solid tumors. Dr. Schuetz will also share the companys progress on CTX-8371, a novel PD-1/PD-L1 bispecific, which has shown significantly increased activity in preclinical testing compared to PD-1 or PD-L1 monoclonal antibody therapies available commercially.

The presentation details are:

Date: Tuesday, March 3, 2020Time: 11:00 11:25 a.m. ETLocation: Boston Marriott Copley Place

About Compass Therapeutics

Compass Therapeutics is a clinical-stage biotechnology company targeting the human immune synapse with a new generation of monoclonal and multispecific antibody therapeutics. Compass is leveraging its proprietary StitchMabs and common light-chain based multispecific platforms to empirically identify multispecifics and combinations of antibody therapeutics that synergistically modulate key nodes in the immune system. The companys lead product candidate, CTX-471, is a fully human agonistic antibody of CD137, which is in a Phase 1 study in patients with inadequate responses to PD-1/PD-L1 checkpoint inhibitors. Compass is also progressing several preclinical assets including a novel class of NK cell engaging bispecifics targeting NKp30 and multiple bispecific checkpoint programs. The companys offices and labs are based in Kendall Square in Cambridge, Mass.

Continued here:
Compass Therapeutics to Present at the 40th Cowen Health Care Conference - Business Wire

Will Puma Biotechnology Break Out of Its Rut in 2020? – Motley Fool

Posted on February 29, 2020 by Danzig

Aside from an acquisition, earning marketing approval for a drug candidate is the single biggest event that can happen for a development-stage pharmaceutical company. It marks the beginning of the transition to commercial operations and tends to spark a celebration among investors. But sometimes the celebration is premature.

Puma Biotechnology (NASDAQ:PBYI) offers a particularly painful case study of what can go wrong after a promising drug product launches. The company's breast cancer drug, Nerlynx, was once widely expected to become a blockbuster (a drug that generates over $1 billion in annual sales), but severe side effects have led to high discontinuation rates among patients. Growth virtually stalled in 2019. The pharma stock has fallen over 90% since its peak in late 2017.

While the precipitous fall in the stock price has been terrible for shareholders, Puma Biotechnology has a realistic plan to get Nerlynx back to growth. What do investors need to watch to gauge progress in 2020?

Image source: Getty Images.

Nerlynx is approved as an adjuvant treatment for individuals with early-stage HER2-positive breast cancer who have completed treatment with Herceptin. It disrupts cell signalling processes involved in tumor growth that are enabled by proteins in the HER family.

While Nerlynx is only approved for 12 months of use, most of the first patients to receive the drug discontinued treatment significantly sooner (usually in the first month) due to severe diarrhea. That curtailed year-over-year growth figures beginning in the fifth quarter after launch. Case in point: Full-year 2019 revenue grew just 5% compared to 2018, the drug's first full year on the market.

Investors and Wall Street analysts have been less than forgiving -- and for good reason. But investors would also have to acknowledge that Puma Biotechnology managed the setback for Nerlynx relatively well.

Last year, the business focused on growing product sales (albeit slowly), reducing operating expenses, advancing international partnerships, funding several studies to potentially expand the drug's use, and developing clinically validated regimens for reducing side effects. All of those efforts led to a respectable year of operations in 2019.

Metric

2019

2018

Change (YOY)

Product revenue

$211.6 million

$200.5 million

Total revenue

$272.3 million

$251.0 million

Operating expenses

$311.4 million

$345.7 million

(10%)

Operating income

($39.1 million)

($94.7 million)

N/A

Data source: Company press release. YOY = year over year.

Wall Street isn't looking for respectable operations. Analysts want to see a return to growth before reconsidering the company's $450 million market valuation. What can Puma Biotechnology do to deliver on those demands?

Investors will be watching two areas in 2020 to gauge progress:

In late 2019, Puma Biotechnology released data from a study evaluating what antidiarrheal combinations could effectively reduce the severity of diarrhea. Whereas a combination of Nerlynx and loperamide resulted in 20.4% of individuals stopping treatment due to diarrhea and 44.5% discontinuing treatment for any reason (including diarrhea), a combination of Nerlynx, loperamide, and budesonide lowered those discontinuation rates to just 10.9% and 20.3%, respectively.

More promising, doctors found that combining a dose escalation regimen of Nerlynx with loperamide led to just 3.3% of individuals stopping treatment due to diarrhea and 20% discontinuing for any reason.

Puma Biotechnology was quick to put the knowledge into action. In the fourth quarter of 2019, nearly 29% of new patients were started at a reduced dose with the goal of increasing it over the course of treatment. That compares to only 6.6% of patients starting at the reduced dose in the prior-year period.

Investors cannot celebrate yet. During the fourth-quarter 2019 earnings conference call, Puma Biotechnology said it expected the escalating dosing regimen will lower the number of bottles sold initially with an "increase in the potential revenue per patient" in future quarters. In other words, it will take time to know if the new dosing schedule will have the intended effect.

Puma Biotechnology is also eager to expand the use of Nerlynx, which is the only asset in its portfolio and pipeline. There are a number of international regulatory decisions expected soon. Most markets are small, although partner Pierre Fabre launched Nerlynx in select European countries at the end of 2019, while regulators in China are expected to approve the drug in the first half of 2020.

While international sales could create a decent royalty revenue stream for Puma Biotechnology, the company is forging ahead with expanded use in the U.S., where it owns full rights to the drug.

Event

Significance

Decision on supplemental New Drug Application (sNDA) for Nerlynx and Xeloda (a chemotherapy) as third-line treatment for HER2-positive metastatic breast cancer

The U.S. Food and Drug Administration (FDA) is expected to hand down a decision by April 2020. Analysts expect the indication could achieve peak annual sales of $300 million.

Phase 2 results for Control

Positive results over a longer duration could bolster confidence in the new dose escalation regimen. Results expected by the end of 2020.

Phase 2 results for Summit

Exploring the use of Nerlynx in HER2-mutated solid tumor cancers, including breast cancer and cervical cancer. Results expected by the end of 2020.

Data source: Company presentation.

Puma Biotechnology expects to explore additional expansions in HER2-positive breast cancer and HER2-mutated solid tumor cancers, but earning marketing approval for the Nerlynx and Xeloda combination therapy is the nearest and most important potential milestone.

It has certainly been easy to write off Puma Biotechnology in recent years. Nerlynx stumbled in the second full year of its launch due to high discontinuation rates and, considering it's the only asset owned by the company, investors headed for the exits for good reason.

While investors should remain skeptical of the company's ability to pull itself out of its rut, there does appear to be a path forward. The question is whether success is defined by Nerlynx returning to its former blockbuster potential or something far less than that. Unfortunately, investors won't really have enough data points for a few more quarters, although getting the sNDA approved in April could provide a significant boost for the beaten-down stock.

Read the original post:
Will Puma Biotechnology Break Out of Its Rut in 2020? - Motley Fool

Select Page ::